Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Meetings
    • Press Releases
    • Publications
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Meetings
    • Press Releases
    • Publications
  • Contact

Archives

Monthly Archive for: "Marzo, 2016"
Home » Archivi per Marzo 2016
0

Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections

ABSTRACT Human respiratory syncytial virus (HRSV) is a major cause of lower respiratory tract disease in children and the elderly for which there is still no effective vaccine. We have previously [...]

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!